论文部分内容阅读
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who were receiving adequate epoetin doses and who had ferritin levels between 500 and 1200 ng/ml and transferrin saturation (TSAT) ≤25%.The DRIVE-Ⅱ study reported here was a 6-wk observational extension designed to investigate how ferric gluconate impacted epoetin dosage after DRIVE.During DRIVE-Ⅱ, treating nephrologists and anemia managers adjusted doses of epoetin and intravenous iron as clinically indicated.By the end of observation, patients in the ferric gluconate group required significantly less epoetin than their DRIVE dose (mean change of-7527 ± 18,021 IU/wk, P =0.003), whereas the epoetin dose essentially did not change for patients in the control group (mean change of 649 ±19,987 IU/wk, P =0.809).Mean hemoglobin, TSAT, and serum ferritin levels remained higher in the ferric gluconate group than in the control group (P =0.062, P < 0.001, and P =0.014, respectively).Over the entire 12-wk study period (DRIVE plus DRIVE-Ⅱ), the control group experienced significantly more serious adverse events than the ferric gluconate group (incidence rate ratio =1.73, P =0.041).In conclusion, ferric gluconate maintains hemoglobin and allows lower epoetin doses in anemic hemodialysis patients with low TSAT and ferritin levels up to 1200 ng/ml.